论文部分内容阅读
69例应用口服降糖药(OAD)血糖控制不佳的T2DM患者空腹血糖(FBG)≥10mmol/L),随机分为Glargine组30例,中效鱼精蛋白锌人胰岛素(NPH)组39例。FBG水平调整用量,口服阿卡波糖控制餐后血糖(PPG)。治疗目标值FBG<6.1mmol/L,PPG<8.0mmol/L。治疗12周。结果2组患者FBG、PPG均低于治疗前(P<0.05);Glargine联合阿卡波糖组低血糖发生率明显低于NPH组(P<0.05);两组BMI无明显差异。结论Glargine联合阿卡波糖能较好地控制血糖,低血糖发生率低,体重影响小,安全、方便,是T2DM理想的治疗方案。
69 patients with fasting blood glucose (FBG) ≥10mmol / L in patients with poorly controlled blood sugar (OAD) were randomly divided into Glargine group (n = 30) and neutrophil protamine zinc human insulin group (n = 39) . FBG level to adjust the amount of oral acarbose control postprandial blood glucose (PPG). Treatment target value FBG <6.1mmol / L, PPG <8.0mmol / L. Treatment for 12 weeks. Results The FBG and PPG in both groups were lower than those before treatment (P <0.05). The incidence of hypoglycemia in Glargine combined with acarbose group was significantly lower than that in NPH group (P <0.05). There was no significant difference in BMI between the two groups. Conclusion Glargine combined with acarbose can better control blood sugar, low incidence of hypoglycemia, small body weight, safe and convenient, is the ideal treatment for T2DM.